Risk management in the treatment of type 2 diabetes with pioglitazone

Giuseppe Derosa, Sibilla AT SalvadeoDepartment of Internal Medicine and Therapeutics, University of Pavia, Pavia, ItalyIntroduction: Type 2 diabetes mellitus is one of the most important cardiovascular risk factors. Insulin-resistance represents the common mechanism that leads to type 2 diabetes in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Giuseppe Derosa, Sibilla AT Salvadeo
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/c410b88baeb944b1938c2742260003aa
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c410b88baeb944b1938c2742260003aa
record_format	dspace
spelling	oai:doaj.org-article:c410b88baeb944b1938c2742260003aa2021-12-02T00:36:45ZRisk management in the treatment of type 2 diabetes with pioglitazone1178-7007https://doaj.org/article/c410b88baeb944b1938c2742260003aa2009-07-01T00:00:00Zhttp://www.dovepress.com/risk-management-in-the-treatment-of-type-2-diabetes-with-pioglitazone-a3327https://doaj.org/toc/1178-7007Giuseppe Derosa, Sibilla AT SalvadeoDepartment of Internal Medicine and Therapeutics, University of Pavia, Pavia, ItalyIntroduction: Type 2 diabetes mellitus is one of the most important cardiovascular risk factors. Insulin-resistance represents the common mechanism that leads to type 2 diabetes in obese subjects. Pioglitazone is an insulin-sensitizing agent available for treatment of type 2 diabetes. Large clinical trials have demonstrated the effectiveness of pioglitazone in achieving metabolic control and reducing cardiovascular morbidity and mortality.Aim: The purpose of this article is to review the effectiveness and tolerability of pioglitazone in the prevention and management of atherosclerosis in patients with type 2 diabetes. Evidence review: We reviewed the main monotherapy and comparative studies of pioglitazone, and particularly the recent evidence in the field of atherosclerosis and cardiovascular prevention.Place in therapy: The current evidence shows that pioglitazone is an effective option in the treatment of type 2 diabetes. More studies are needed to establish a role for pioglitazone in atherosclerosis prevention beyond glycemic control.Keywords: pioglitazone, diabetes mellitus, glycated hemoglobin, cardiovascular prevention Giuseppe DerosaSibilla AT SalvadeoDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2009, Iss default, Pp 51-60 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Giuseppe Derosa Sibilla AT Salvadeo Risk management in the treatment of type 2 diabetes with pioglitazone
description	Giuseppe Derosa, Sibilla AT SalvadeoDepartment of Internal Medicine and Therapeutics, University of Pavia, Pavia, ItalyIntroduction: Type 2 diabetes mellitus is one of the most important cardiovascular risk factors. Insulin-resistance represents the common mechanism that leads to type 2 diabetes in obese subjects. Pioglitazone is an insulin-sensitizing agent available for treatment of type 2 diabetes. Large clinical trials have demonstrated the effectiveness of pioglitazone in achieving metabolic control and reducing cardiovascular morbidity and mortality.Aim: The purpose of this article is to review the effectiveness and tolerability of pioglitazone in the prevention and management of atherosclerosis in patients with type 2 diabetes. Evidence review: We reviewed the main monotherapy and comparative studies of pioglitazone, and particularly the recent evidence in the field of atherosclerosis and cardiovascular prevention.Place in therapy: The current evidence shows that pioglitazone is an effective option in the treatment of type 2 diabetes. More studies are needed to establish a role for pioglitazone in atherosclerosis prevention beyond glycemic control.Keywords: pioglitazone, diabetes mellitus, glycated hemoglobin, cardiovascular prevention
format	article
author	Giuseppe Derosa Sibilla AT Salvadeo
author_facet	Giuseppe Derosa Sibilla AT Salvadeo
author_sort	Giuseppe Derosa
title	Risk management in the treatment of type 2 diabetes with pioglitazone
title_short	Risk management in the treatment of type 2 diabetes with pioglitazone
title_full	Risk management in the treatment of type 2 diabetes with pioglitazone
title_fullStr	Risk management in the treatment of type 2 diabetes with pioglitazone
title_full_unstemmed	Risk management in the treatment of type 2 diabetes with pioglitazone
title_sort	risk management in the treatment of type 2 diabetes with pioglitazone
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/c410b88baeb944b1938c2742260003aa
work_keys_str_mv	AT giuseppederosa riskmanagementinthetreatmentoftype2diabeteswithpioglitazone AT sibillaatsalvadeo riskmanagementinthetreatmentoftype2diabeteswithpioglitazone
_version_	1718403645401202688

Risk management in the treatment of type 2 diabetes with pioglitazone

Ejemplares similares